Overview

• U.S. medical technology firm's Q1 sales rose 5%, beating analyst expectations

• Adjusted EPS for Q1 beat analyst expectations

• Growth driven by new product launches, partly offset by fewer selling days

Outlook

• Enovis reaffirms 2026 revenue guidance of $2.31-2.37 bln, with 4-6% organic growth

• Company expects 2026 adjusted EBITDA of $425-435 mln

• Enovis sees 2026 adjusted EPS at $3.52 to $3.73 and free cash flow conversion of 25% or higher

Result Drivers

• RECONSTRUCTIVE SEGMENT - Co said Q1 growth was driven by 11% reported sales growth in Reconstructive, supported by new product launches

• FEWER SELLING DAYS - Co said growth was partly offset by the impact of fewer selling days in the quarter

Company press release: ID:nGNX7h0kB8

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Sales	Beat	$589.15 mln	$571.13 mln (11 Analysts)
Q1 Adjusted EPS	Beat	$0.89	$0.82 (11 Analysts)
Q1 Gross Margin		62.00%

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Enovis Corp is $45.00, about 81.1% above its May 6 closing price of $24.85

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.